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GOODPASTURE SYNDROME: AN INVESTIGATION OF
DISEASE PROCESS, DIAGNOSIS, TREATMENT, AND
CONTRIBUTION TO INTRAPULMONARY HEMORRHAGE
JULIA SHIELD, QUEENSLAND UNIVERSITY OF TECHNOLOGY
MENTOR: MARK B. PLENDERLEITH
Abstract
Goodpasture syndrome is a rare autoimmune disorder affecting
approximately one person per million. It is caused by the development of antiglomerular basement membrane (GBM) antibodies. Since the description of
Goodpasture syndrome in 1958, understanding of the syndrome’s pathophysiology
has significantly increased with advances in molecular biology, delineation of
immune function, and research into the structure and function of collagen, which
forms the basement membranes in the alveoli and glomeruli. Although the exact
trigger for the development of these autoantibodies is unknown, there is a clear
genetic predisposition in affected individuals with a correlation to human leukocyte
antigen (HLA) alleles in anti-GBM disease. Environmental factors such as viral
infection and smoking then damage the alveoli, causing increased permeability and
increased access to the basement membrane for the autoantibodies. The
autoimmune response attacks the basement membrane of both alveoli and
glomeruli, causing pulmonary hemorrhage, hemoptysis, anemia, respiratory failure,
glomerulonephritis, and renal failure. It is diagnosed by a combination of
respiratory function tests, chest X-ray, serology for anti-GBM antibodies, and renal
biopsy. A renal biopsy reveals crescentic glomerulonephritis and linear
immunofluorescent staining from autoantibody deposition in the capillaries.
Disease progress is monitored by using these tests serially. Treatment involves
immunosuppressive medications such as corticosteroids and cyclophosphamide to
prevent autoantibody production, as well as plasmapheresis to remove
autoantibodies from circulation. Novel treatment methods currently under
investigation include immunoadsorption, cryofiltration, and enzymatic
degradation. Immunoadsorption is a developing therapy with early results showing
high effectiveness, but further trials are necessary. New developments for using
enzymatic proteins from the Streptococcus pyogenes bacteria to remove anti-GBM
autoantibodies that are bound to the actual basement membrane and not just those
in circulation are currently under investigation. This is facilitated by further recent
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advances in delineating collagen molecular structure composition in the basement
membrane. Provided Goodpasture syndrome is diagnosed early, treatment
regimens are very effective in controlling the disease; however, late-stage disease
requires dialysis and lung or kidney transplantation. As advances in molecular
biology and genetics continue, the immune function is mapped in greater detail,
and genetic susceptibility is better understood, more opportunities to treat
autoimmune conditions such as Goodpasture syndrome will develop.
Goodpasture syndrome is a rare autoimmune disorder characterized by the
destruction of the basement membrane in both the lungs and kidneys (Zhong et al.,
2020). Circulating anti-glomerular basement membrane (GBM) antibodies attach
to collagen-fiber networks in the membrane, which triggers the membrane’s
destruction, causing alveolar hemorrhage, resulting in anemia and respiratory
failure due to impaired gas exchange (Greco et al., 2015). Alveolar hemorrhaging
from basement-membrane breakdown causes dyspnea, hemoptysis, and chest pain
(Huart et al., 2016). Given the potential severity of these clinical manifestations,
pulmonary abnormalities usually become evident before respiratory failure
develops; however, a rapid diagnosis is essential, as hemorrhage is the leading
cause of death in individuals with Goodpasture syndrome (Nasser & Cottin, 2018).
Although the exact trigger of this antibody-induced autoimmune response remains
unknown, certain environmental factors (e.g., chemical or infectious exposure)
coupled with genetic susceptibility may lead to its development (Pedchenko et al.,
2018). Diagnosis is achieved by a combined interpretation of respiratory function
testing, antibody detection through serology, chest X-ray, and lung or kidney
biopsy. Patients diagnosed with Goodpasture syndrome undergo an array of
treatment depending on the severity of their condition. Commonly used therapies
include plasmapheresis, immunosuppression, renal dialysis, and organ
transplantation. Emerging research has provided numerous opportunities for
alternative methods of treatment in the near future. The following review will
utilize current literature and research to investigate the history, epidemiology,
etiology, and pathophysiology of Goodpasture syndrome. The most common forms
of diagnostic and treatment procedures will be analyzed. Additional insights for
emerging research in the field will also be discussed.
Literature Review
This review will begin by highlighting the initial investigations of
Goodpasture syndrome, proceeded by more modernized approaches by relating

227

BUTLER JOURNAL OF UNDERGRADUATE RESEARCH, VOLUME 7

incidence of alveolar hemorrhage to renal failure. Discussion will turn to further
analysis of contrasting clinical manifestations, diagnostic methods, and treatments.
Goodpasture syndrome was first described in 1958 by Australian scientists
Stanton and Tange (Pedchenko et al., 2018), who reported nine cases of rare
glomerulonephritis with close association to events of idiopathic pulmonary
hemorrhage. One case study described a man admitted to hospital with anemia,
hemoptysis, and signs of bronchopneumonia in the right lung and who died after
three days (Collins, 2010). Urinalysis showed traces of albumin, which is indicative
of glomerulonephritis. A postmortem examination showed that the terminal
bronchioles filled with erythrocytes, in addition to necrosis of the alveolar walls
(Collins, 2010). The authors named the disease in recognition of similar case
reports described by Dr. Ernest Goodpasture in his 1919 publication on the etiology
of influenza (Greco et al., 2015). At that time, similar clinical presentations of lung
hemorrhage linked with glomerulonephritis were attributed to atypical influenza
infection. Not until the detection of anti-GBM antibodies in the 1960s was a clinical
description of the pathogenesis for autoimmune-induced Goodpasture syndrome
possible (Gulati & McAdoo, 2018).
Since its establishment in 1986, the Vasculitis Foundation has provided
research funding, educational resources, and networking opportunities for patients
affected by Goodpasture syndrome and other closely related diseases (National
Organization for Rare Disorders, 2019). Given the rarity of the disorder, archives
like these allow continued investigation into the pathophysiological processes and
controversial etiological implications of the disease. Consequently, the best
possible diagnosis and treatment options for patients can be provided as research
progresses.
Epidemiology and Incidence
Goodpasture syndrome is a rare disorder, with 0.5 to 1.8 cases per million
individuals, according to a study published in 2016 that monitored disease numbers
across 26 countries (Canney et al., 2016). This is similar to previous approximations
of 1 to 2 cases per million individuals each year across Caucasian populations
(Gulati & McAdoo, 2018). Some studies report that the disease is more common in
males than in females, with a 6:1 occurrence ratio (Kaewpu et al., 2020), but an
investigation from the University of Bari found no significant difference in
incidence between gender for affected individuals (Dammacco et al., 2013).
Goodpasture syndrome has a bimodal age distribution, primarily affecting
individuals between 20 and 30 years and between 60 and 70 years (Betsy et al.,
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2019). Furthermore, it is most common in adults with Caucasian or European
descent, with African populations less likely affected (Marques et al., 2020).
Etiology
Goodpasture syndrome is caused by the production of anti-GBM
autoantibodies that travel through the bloodstream and mediate the destruction of
the alveolar and glomerular basement membranes (Nasser & Cottin, 2018). The
specific trigger for the development of these autoantibodies is not fully understood.
Certain genetic and environmental influences may contribute to the development
of this disorder, however (Pedchenko et al., 2018).
Cases of Goodpasture syndrome are often reported occurring among
families, which suggests a genetic susceptibility (Gulati & McAdoo, 2018). There
is a clear correlation with human-leukocyte antigen (HLA) alleles in anti-GBM
disease, with the antigen HLA-DR15 being found in 88% of affected individuals
(Nasser & Cottin, 2018). Environmental factors including viruses may contribute
to the development of the disease by enacting antibodies to fight infection, which
then cross-react against the basement membrane. Consequently, the body’s
immune defenses can attack surrounding healthy tissue (Marques et al., 2020).
Pulmonary hemorrhage is also closely associated with smoking, as cigarette
contents break down the thin alveolar lining and surrounding capillaries (Nasser &
Cottin, 2018).
Pathophysiology
As discussed, Goodpasture syndrome is caused by the destruction of
alveolar and glomerular basement membrane by circulating anti-GBM
autoantibodies. To understand how this process occurs, we must first understand
the structure and function of antibodies and basement membranes. Investigation
will turn to the development of secondary outcomes and disruption of the
physiological processes involved in respiration.
The autoantibodies reactive with the alveolar and glomerular basement
membranes are from the IgG class. Pathological antibodies also belong to this class,
but anti-GBM antibodies belong to subclasses IgG2 and IgG4, which enable
variation in the fragment antigen-binding domains and therefore specificity in
binding (Gulati & McAdoo, 2018). Such observations show the significance of
evaluating the structural and binding features of autoantibodies to understand their
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ability to trigger an autoimmune response and therefore the pathogenesis of
Goodpasture syndrome.
Alveolar basement membranes are extracellular matrices comprising type
IV collagen, heparan sulphate proteoglycan, laminin, and nidogen (Gulati &
McAdoo, 2018). Six alpha chains compose the collagen IV family, which bind to
form unique triple-helical protomer structures (Pedchenko et al., 2018). These
polymerize to form hexametric structures that provide support to overlying cells. In
the basement membrane, type IV collagen networks in their native form are
arranged into triple-helical protomers from α3, α4, and α5 chains (Zhong et al.,
2020). These domains associate to produce the hexameric-NC1 domain. The
quaternary structure becomes reinforced by hydrophilic, hydrophobic, and
disulphide bonds across separate domains (Gulati & McAdoo, 2018), and these
polymerize with other like units to form a lattice network of collagen, as shown in
Figure 1 (McAdoo & Pusey, 2017). The NC1 domains of collagen protomers arise
in specific combinations that produce linear arrays found in both the lungs and
kidneys.
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Figure 1. Collagenous Structure of the Alveolar and Glomerular Basement Membrane
Note. Panels A and B: Structure consists initially of α3, α4, and α5 chains to produce a
triple helical protomer. Panel C: Association of these protomers produces the
hexametric NC1 domain. Panel D: Multiple domains bind by hydrophilic and
hydrophobic interactions to form the lattice structure found in α3(IV)NC1 collagen
networks. From “Anti-Glomerular Basement Membrane Disease,” by S. McAdoo and C.
Pusey, 2017, Clinical Journal of the American Society of Nephrology, 12(7), 1162-1172
(https://doi.org/10.2215/CJN.01380217).

The core target for circulating anti-GBM antibodies is the noncollagenous
domain (NC1) in the α3 chain of type IV collagen, or α3(IV)NC1 (Gulati &
McAdoo, 2018). This molecule contains two epitopes, EA and EB, where antibodies
bind, allowing T-cell recognition to promote a humoral immune response. This is
also known as the self-antigen, which triggers the autoimmune response in
Goodpasture syndrome after antibody binding is initiated (Zhong et al., 2020).
Specific binding of antibodies to the alveolar basement membrane is enabled by the
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epitopes on self-antigens as well as the arrangement of collagen chains allowing
easy access to traveling antibodies. In a healthy individual, endothelia in alveoli
provide a protective barrier so anti-GBM antibodies are unable to bind to these
epitopes (Hudson et al., 2019), but antibodies can more efficiently bind to the
epitope units in collagen domains of the basement membrane because of increased
permeability from either increased capillary hydrostatic pressure or environmental
factors including smoking and hydrocarbon exposure or pathogenic infection in the
alveoli (Pedchenko et al., 2018).
A strong correlation has been shown with Goodpasture syndrome and the
HLA system. This system aids in human immunity by determining the difference
between self- and non-self-antigens. HLA-DR15 is one such HLA located in about
88% of people affected by Goodpasture syndrome (Nasser & Cottin, 2018). The
high prevalence of these alleles within individuals with the disease highlights a
potential-genetic predisposition for this rare autoimmune disease; however, certain
alleles involved with the HLA system are fairly common among unaffected
populations, suggesting that additional factors are involved in development of the
disease (Pedchenko et al., 2018). Additionally, a study released in 2016 investigated
spatial and temporal clustering of cases, which indicates that the presence of
environmental factors may contribute to provoking disease (Marques et al., 2020).
Some preexisting damage to the alveolar lining is essential to allow the increased
permeability that provides access for autoantibodies. Binding can then occur on the
epitopes on the self-antigens of membranous subunits and activate cascade
reactions that ultimately result in injury to the lining (Nasser & Cottin, 2018).
The binding of antibodies to the basement membrane triggers a response via
two effector mechanisms. In the first, inflammatory processes are activated, which
enables the mobilization of leukocytes and inflammatory mediators, forming the
lytic membrane attack complex. The second response involves binding of Fc
receptors (FcγR) by anti-GBM antibodies (Dammacco et al., 2013). This binding
action activates phagocytosis and antibody-dependent cellular cytotoxicity to
produce a strong autoimmune response. There remains a distinguishable correlation
between the presence of HLA and anti-GBM antibodies in Goodpasture syndrome.
HLA is a gene complex for major histocompatibility complex (MHC) proteins,
which help regulate human immunity (Hudson et al., 2019). This shows that T cells
must be activated before autoantibodies can be generated. After being activated by
T-helper (Th) lymphocytes, macrophage cells arrive at the site of antibody
accumulation and produce interferon-(IFN)-γ and interleukin (IL)-12 (Dammacco
et al., 2013). These cytokines, along with all accumulated cells, induce structural
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change within the matrix of proteins in the membrane, causing mechanical
weakness, which leads to eventual irreversible damage. Th1 specific memory cells
also migrate to the site of inflammation to initiate a delayed hypersensitivity
response (Zhong et al., 2020). This contributes to most of the damage over time
once the initial response has been established.
The complete pathogenic process by which basement membrane destruction
arises in lungs and kidneys affected with Goodpasture syndrome is illustrated in
Figure 2.

Figure 2. Pathogenic Procedure of Goodpasture Syndrome Leading to Both Pulmonary
and Renal Damage
Note. Collagenous protomers form with EA and EB epitopes on the α3 collagen chain.
Disruption of hexamer structure by environmental influences causes exposure of
epitopes, which allows binding of anti-GBM autoantibodies in genetically susceptible
individuals. Cellular effectors contribute to damage and inflammation of the basement
membrane via the autoimmune response. From “Anti–Glomerular Basement
Membrane Disease,” by K. Gulati and S. McAdoo, 2018, Rheumatic Disease Clinics of
North America, 44(4), 651-673 https://doi.org/10.1016/j.rdc.2018.06.011).
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Significant damage to the collagenous microstructure in the alveolar
basement membrane in turn damages the surrounding alveolar capillaries, causing
mass hemorrhaging into the alveolar space. The high capacitance but low pressure
in the-pulmonary-circulation causes chronic low-grade hemorrhage (Greco et al.,
2015). The secondary manifestations of hemoptysis and anemia may consequently
arise. Gas exchange still occurs with the blood pooled in the alveoli, although
oxygenation for blood still traveling throughout the pulmonary circulation is no
longer possible. This can lead to alveolar collapse, ultimately causing hypoxemia
(Kusunoki et al, 2018). In more-severe cases, this can lead to respiratory failure and
death.
Clinical Features and Symptoms
The most significant feature of Goodpasture syndrome is pulmonary
hemorrhage leading to hemoptysis (Huart et al., 2016). Severity can range from
coughing up specks to large volumes of blood. Approximately 80%-90% of patients
will present with rapidly progressive glomerulonephritis, whereas 40%-60% of
patients will experience alveolar hemorrhage (McAdoo & Pusey, 2017). Dyspnea
and chest pain may also precede. Most affected individuals experience hematuria;
however, glomerulonephritis and acute renal failure can develop weeks to years
after the onset of pulmonary symptoms (Henderson & Salama, 2017).
Approximately 60%-80% of patients with Goodpasture syndrome develop clinical
manifestations of both pulmonary and renal disease, whereas 20%-40% experience
disease limited to the kidneys. Fewer than 10% have pulmonary disease alone
(Stojkovikj et al., 2016). The occurrence of clinical and pathological features
observed in patients is summarized in Figure 3.
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Figure 3. Summary of Major Clinical and Immunological Features of Patients with
Goodpasture Syndrome
Note. A range of symptoms from patients was observed, as were the presence of antiGBM autoantibodies and proteinuria as a sign of renal failure. From “Anti-Glomerular
Basement Membrane Disease,” by S. McAdoo and C. Pusey, 2017, Clinical Journal of
the American Society of Nephrology, 12(7), 1162-1172
(https://doi.org/10.2215/CJN.01380217).

Diagnosis
Diagnosis of Goodpasture syndrome involves the accumulation of results
from serology, renal biopsy, and chest X-ray to create an overall indication of the
patient’s state. Other tests, such as respiratory function testing, are not routinely
performed but may be used to indicate signs of hemorrhage in the lungs. The
disease can become rapidly progressive and fatal if identification and subsequent
treatment are delayed. Results must therefore be quickly obtained to ensure the best
possible outcome for the affected individual.
Serology Test
Detection of anti-GBM autoantibodies is the most common method of
diagnosing
Goodpasture
syndrome.
Procedures
including
indirect
immunofluorescence testing and direct enzyme-linked immunosorbent assay
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(ELISA) are used to detect the autoantibodies and confirm diagnosis (Zhong et al.,
2020).
Assays generally have high specificity and sensitivity, although 5%-10% of
patients showing anti-GBM antibodies from renal biopsy had false-negative
serology results when using the assay detection method (Gulati & McAdoo, 2018).
According to a study by Gulati and McAdoo (2018), this can result from intrinsic
sensitivity of the assay, antibody disappearance before clinical resolution, or highaffinity antibodies being rapidly removed from circulation. Similarly, a study by
Henderson and Salama (2017) found that the ELISA method showed a high
sensitivity of 95%-100% but a varying specificity of 90%-100%. Serologic testing
is an urgent laboratory test and can produce tangible results within 24 hours. A
patient affected by Goodpasture syndrome can deteriorate quickly, so rapid
diagnosis is essential to early treatment. Approximately 10% of patients with
Goodpasture syndrome do not always have identifiable antibodies with
conventional assays, however, so serologic testing should not be the only diagnostic
procedure performed (McAdoo & Pusey, 2017). If the patient presents with signs
of glomerulonephritis but no anti-GBM antibodies are detected, a renal biopsy will
be performed.
Renal Biopsy
Because of a higher risk of damage, lung biopsy samples are not regularly
used to diagnose Goodpasture syndrome. Instead, renal biopsy, in combination with
a serum assay for anti-GBM antibodies, is preferred and provides a higher yield of
sample. The procedure involves collecting a sample of kidney tissue that is
examined using both light and immunofluorescent microscopy to reveal structural
or necrotic changes in the glomeruli and lines of antibodies attached to the basement
membrane, as seen in Figure 4 (Gulati & McAdoo, 2018). Immunofluorescent
staining of tissue reveals a linear deposition of IgG antibodies along the alveolar
and glomerular capillaries. Such findings are an indication of Goodpasture
syndrome. Crescent formation in the glomerular tissue is a histopathologic effect
of anti-GBM disease. Findings from a study by McAdoo and Pusey (2017) suggest
that 95% of affected individuals have crescent formation of the glomeruli revealed
by a kidney biopsy. The number of observed crescents in the tissue correlates with
the level of damage to the kidney.
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Figure 4. Kidney Biopsy Sample Using Light Microscopy and Immunofluorescence
Microscopy for IgG Antibodies
Note. Panel A: Acute crescent formation shows disruption of the basement membrane
due to fibrinoid necrosis. Panel B: Antibody deposits are revealed along the basement
membrane, with weaker staining highlighting signs of tissue damage. From “AntiGlomerular Basement Membrane Disease,” by K. Gulati and S. McAdoo, 2018,
Rheumatic Disease Clinics of North America, 44(4), 651-673
(https://doi.org/10.1016/j.rdc.2018.06.011).

Chest X-ray
A crucial step in the diagnosis of Goodpasture syndrome is detecting the
presence of hemorrhage within the lung. This is achieved by performing an X-ray
or CT scan of the thorax. In about 80% of affected individuals, chest X-rays reveal
bilateral frosted-glass opacities within alveolar regions, as shown in Figure 5
(Marques et al., 2020). The costophrenic angles and apices of the lungs usually
remain unaffected. Where diagnosis of lung hemorrhage remains uncertain, a
bronchoscopy is performed. Diagnosis is based on the absence of bronchial lesions
which may have led to the alveoli filling with blood from erosion (Marques et al.,
2020). Identification of pulmonary hemorrhage via X-ray is widely accepted,
although appearance overlaps pulmonary edema (Li et al., 2020), so in the diagnosis
of Goodpasture syndrome, this method must be included with a respiratory function
test and antibody detection.
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Figure 5. Chest Radiograph of Normal Lungs and Frosted-Glass Opacities
Note. Left panel: Normal lungs. Right panel: Frosted-glass opacities in the lungs caused
by alveolar hemorrhage. From Comprehensive Clinical Nephrology (5th ed.), by J.
Floege, R. Johnson, and J. Feehally, 2015
(https://www.elsevier.com/books/comprehensive-clinical-nephrology/johnson/978-14557-5838-8).

The main issue regarding diagnosis of this pathology is an extensive
timeframe, resulting in delayed treatment. As each test cannot provide a definitive
diagnosis individually, gathering multiple test results before determining the
patient’s overall state is timely where disease can rapidly progress. Detection of
anti-GBM antibodies using the serology technique is perhaps the most important
step in diagnosing Goodpasture syndrome. Despite this technique’s rapid
completion time, the occurrence of false-negative results reduces its overall
reliability, and it cannot be used as a sole diagnostic procedure (McAdoo & Pusey,
2017). As laboratory antigen-detection techniques continue to advance, however,
the quality of such findings is set to improve for future patients.
Respiratory Function Testing
Patients affected with Goodpasture syndrome will produce a quantitative
change in breathing pattern when assessed by a clinical physiologist using a
respiratory function test, although this test is not routinely performed. By
incorporating a standard breathing technique, estimations of diffusing capacity after
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the inhalation of carbon monoxide can be used to monitor the progression of
intrapulmonary hemorrhage (Ewan et al., 2019). In the test, the patient inhales a
gas mixture, which diffuses into the pulmonary capillaries from the alveoli. Carbon
monoxide uptake depends on the availability of hemoglobin for binding and is
represented by the rate constant for carbon monoxide transfer (kCO). When
hemorrhaging has occurred, the alveoli fill with extravascular blood, which allows
the uptake of additional carbon monoxide (McAdoo & Pusey, 2017). As the
diffusion of gas from alveolar space to pulmonary capillary is the rate-determining
step, the removal of this process increases the efficiency by which carbon monoxide
binds to hemoglobin, overestimating the rate of transfer. The kCO will therefore
appear abnormally high when corrected for the reduced hemoglobin levels
(Martínez-Martínez et al., 2017).
A study published in the British Medical Journal performed the respiratory
function test on 11 patients with Goodpasture syndrome to determine their kCO
values in comparison to predicted normal values based on height, gender, and
ethnicity. As shown in Table 1, kCO values corrected for hemoglobin levels were
greater than predicted values for most patients (Ewan et al., 2019). This shows that,
while patients are anemic, high levels of gas diffusion are taking place inside the
lung due to pooling of blood from alveolar hemorrhage. Measuring carbon
monoxide intake with the respiratory function test delivers a noninvasive and
repeatable indication of lung hemorrhage as seen in Goodpasture syndrome
(McAdoo & Pusey, 2017).
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Table 1. kCO and Hemoglobin Measurements from Respiratory Function Testing for Patients With Goodpasture Syndrome

Patient
Hemoglobin

1

2

3

4

5

6

7

8

9

10

11

6.7

7.5

7.9

5.7

5.3

9.1

7.9

7.2

7.8

7.0

12.1

8.5

7.1

8.8

8.2

7.1

8.5

8.3

7.3

8.2

7.7

6.0

15.0

5.3

13.7

14.8

8.6

10.4

17.4

17.2

12.0

13.0

10.5

176

-75

156

180

121

122

210

236

146

169

175

(g/dl)
Predicted normal
kCO (%sec-1)
kCO hemoglobin
corrected (%sec-1)
% kCO change

Note. From “Detection of Intrapulmonary Hemorrhage With Carbon Monoxide Uptake—Application in
Goodpasture’s Syndrome,” by P. Ewan, H. Jones, C. Rhodes, and J. Hughes, 2019, The New England Journal of
Medicine, 295(25), 1391-1396 (https://doi.org/10.1056/NEJM197612162952502).

240

BUTLER JOURNAL OF UNDERGRADUATE RESEARCH, VOLUME 7

Treatment
Multiple treatment options for Goodpasture syndrome target the anti-GBM
antibodies that destroy the alveolar and glomerular basement membrane in an
autoimmune response. Despite the rarity of this disorder, options to treat both
aggressive and nonaggressive stages have become available because of recent
advancements in biomedical technology. Management must immediately follow
diagnosis, as the disease progresses rapidly and can become fatal. Rapid
implementation of appropriate treatment initially involved discriminating
Goodpasture syndrome from other similar pulmonary syndromes. Starting therapy
despite a negative result for anti-GBM antibodies is still essential, as delay can lead
to progression of the disease. Therapies currently used include plasmapheresis and
immunosuppression involving corticosteroid medications. More-severe stages may
require dialysis and organ transplantation. Treatment for Goodpasture syndrome
involves three goals: rapid removal of autoantibodies from circulation, prevention
of further autoantibody production, and removal of potentially harmful agents
produced from the initial immune response (Nasser & Cottin, 2018).
Plasmapheresis
The rapid removal of circulating autoantibodies is achieved by
plasmapheresis. Even if the patient has not yet been diagnosed with Goodpasture
syndrome, plasmapheresis can commence following a case of severe pulmonary
hemorrhage (Greco et al., 2015). The role of plasmapheresis is to remove unwanted
toxins such as anti-GBM antibodies from the blood, thus eliminating the risk of an
autoimmune response in the alveoli. In the procedure, blood is removed from the
patient and the cellular contents and plasma are separated. Donated human-plasma
replaces the patient’s-original plasma, and then the blood with the donated plasma
is transfused back into the patient (Saladi et al., 2018). If a bleeding risk occurs
after pulmonary hemorrhage or renal biopsy in patients, fresh frozen plasma is
added to maintain normal coagulation. Plasma exchanges of about four liters are
performed daily for two to three weeks or until anti-GBM antibodies are no longer
detected (Pedchenko et al., 2018). Despite the usefulness of plasmapheresis in
ridding the blood of harmful autoantibodies, research regarding side effects and
overall efficacy is ongoing.
A study published in 2014 involving 28 patients diagnosed with
Goodpasture syndrome compared the plasma-exchange methods of plasmapheresis
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and immunoadsorption. Findings show that both methods produced similar levels
of effectiveness, with 59.0% and 71.2% efficacy respectively, although only 62.7%
of patients undergoing plasmapheresis had reduced IgG, compared to 83.5% of
those undergoing immunoadsorption (Pedchenko et al., 2018). Despite these
differences, the plasmapheresis group overall experienced fewer plasma-associated
side effects, making plasmapheresis a safer method of plasma exchange.
Immunoadsorption is another method of serum-antibody removal that is
used for multiple autoimmune diseases involving antibody-mediated rejection
(Saladi et al., 2018). Advocates have proposed immunoadsorption as a therapy in
anti-GBM disease because of its high-affinity binding of IgG antibody subclasses
and redundancy of fresh frozen plasma. With this technique, about 87% of IgG
antibodies can be removed from 2.5 plasma volumes in one session. More than 98%
of IgG can be cleared after multiple sessions (Henderson & Salama, 2017).
Plasmapheresis is still the preferred therapy for Goodpasture syndrome, as the
involvement of immunoadsorption in anti-GBM disease is yet to be properly
evaluated. Minor case studies of the immunoadsorption method among 10 patients
showed that antibody levels declined approximately 71%-84% after the initial
therapy (Henderson & Salama, 2017). This is an improvement on report cases
involving the plasmapheresis method, but it is not comparable to studies involving
larger numbers of patients. More investigation into the large-scale effectiveness of
immunoadsorption is therefore necessary before immunoadsorption can become
the preferred plasma-exchange treatment for Goodpasture syndrome.
Immunosuppression
The prevention of ongoing anti-GBM antibody production is achieved via
immunosuppression drugs such as corticosteroids and cyclophosphamide. It can
also prevent rebound hypersynthesis of antibodies after the cessation of
plasmapheresis (Greco et al., 2015). Reduction of the body’s immune response
reduces activity of circulating antibodies, including the anti-GBM antibodies, long
term. This helps lower the occurrence of autoantibody-induced destruction of the
basement membranous structure in the alveoli and glomeruli. Reduction in the
body’s ability to produce an immune response consequently leads to a higher risk
of viral and bacterial infections within patients (Gulati & McAdoo, 2018).
Corticosteroids and cyclophosphamide are initially administered for 6 and 3
months, respectively, to reduce immune activity and maintain leucocyte levels in
the blood (Greco et al., 2015). Therapy durations are not well defined, so the
presence of anti-GBM antibodies is regularly monitored. Individuals with
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serologically active disease require an extended period of immunosuppression at
around 6-9 months. Oral cyclophosphamide is used, as a 2012 study showed that
intravenously administered cyclophosphamide was linked with increased mortality
in patients with Goodpasture syndrome (Gulati & McAdoo, 2018). Both rituximab
and mycophenolate are used as alternative options in treating anti-GBM antibody
disease if cyclophosphamide use fails or yields severe side effects (Henderson &
Salama, 2017). The anti-GBM antibodies become undetectable but produce
variable renal outcomes.
Following immunosuppressive treatments, adverse side effects, including
interstitial pneumonitis, erythrocyte aplasia, and thrombocytopenia, are common
(Diehl et al., 2017). The consumption of such drugs therefore must be carefully
planned and monitored by a healthcare professional throughout the course of
treatment. Dosing of 375 milligrams/m2 intravenously once weekly is
recommended for rituximab, 0.5-3 grams/day for mycophenolate, and 500-1000
milligrams/m² intravenously monthly for six doses, plus corticosteroids for
cyclophosphamide (Medscape, 2021a, 2021b, 2021c). Anti-GBM antibody titers
must be monitored regularly. Once antibody becomes consecutively undetectable,
plasmapheresis is terminated. Antibody titer procedures are performed monthly as
a follow-up for at least six months. Corticosteroids are continued for a minimum of
six months, and cyclophosphamide for three months to help eliminate any
persisting anti-GBM antibody levels in patients (Segelmark & Hellmark, 2019).
Substantial evidence supports the effectiveness of plasmapheresis and
immunosuppression as methods for treating Goodpasture syndrome. One five-year
study demonstrated that immunosuppressive methods combined with
plasmapheresis were more effective than was immunosuppression alone (Chung,
2019). This is because anti-GBM antibodies are more efficiently removed, allowing
for faster patient recovery and less tissue damage. A research study conducted on
the molecular basis of Goodpasture syndrome compared the effects of
immunosuppression therapy with and without the use of plasmapheresis and found
the mortality rate decreased 11% with the combined treatment (Betsy et al., 2019).
This shows that although each treatment method is effective in alleviating the
consequences of the autoimmune response, the best possible outcome for the
patient is achieved when both therapies are employed simultaneously.
Dialysis
The final goal in treatment for Goodpasture syndrome is the removal of
potentially harmful agents generated from the initial immune response. This
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involves dialysis or the removal of excess toxins and solutes from the blood.
Because of glomerular membrane damage, patients need regular checks to monitor
renal function (Saladi et al., 2018). If the kidney can no longer function to an
adequate level, dialysis will be performed indefinitely as a replacement therapy.
Referral for organ transplantation may additionally be recommended, depending on
suitability and availability. End-stage renal disease is still possible after renal
dialysis, though only about 30% of surviving patients require this treatment method
(Pedchenko et al., 2018).
Organ Transplantation
In the most severe cases of Goodpasture syndrome, affected individuals
may receive lung or kidney transplants, depending on the level of original function
lost. Patients who receive transplants can have a recurrence of anti-GBM antibody
levels, causing relapse (Gulati & McAdoo, 2018). A patient should therefore wait
about six months after plasmapheresis and immunosuppression before receiving a
transplant, to ensure seronegativity with anti-GBM antibodies. This will reduce the
risk of damage to the transplanted organ. Relapses are uncommon, however, and
are associated with prolonged exposure to environmental factors such as irritants
and smoking (Rohm et al., 2019).
Future Directions
There are several emerging directions for the management and treatment of
Goodpasture syndrome. As research on this rare disease progresses, new
mechanisms for understanding pathogenesis and treatment are under development.
Collagen research and novel methods of plasma exchange are some of the areas
currently under investigation.
Research regarding the type IV collagen family provides new information
about the structural development of basement membranes in the alveoli and
glomeruli. By understanding the biochemical nature of these collagen molecules
acting as antigens in the autoimmune response, the molecular understanding of
protomer assembly in the pathogenesis of Goodpasture syndrome can be better
understood (Hudson et al., 2019). Certain developing insights suggesting
membranous susceptibility to proteolysis can lead to the development of certain
protease inhibitors and genetic therapy. Experimental models of this disease predict
the potential use for costimulatory blockade of T-cell activation or prevention of
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macrophage migration (Hudson et al., 2019). This work will provide a new
understanding of collagen-related diseases such as Goodpasture syndrome.
More specific methods of plasmapheresis are being investigated for the
treatment of Goodpasture syndrome. Some of these include immunoadsorption,
cryofiltration, and enzymatic degradation. Current methods of plasma exchange are
useful for removing anti-GBM antibodies that are in circulation but not those bound
to tissue (Henderson & Salama, 2017). New approaches to this problem are under
investigation, including exploration of the properties of proteins S. pyogenes (IdeS)
and endoglycosidase (EndoS), which are secreted by the bacteria Streptococcus
pyogenes. Human IgG antibodies are cleaved by IdeS, which produces monomeric
Fc fragments (Henderson & Salama, 2017). This hinders the antibody’s ability to
function. An experimental model of glomerulonephritis demonstrated the
successful removal of glomerular Fc fragments of anti-GBM by IdeS, showing its
effectiveness as an immunosuppressant. IdeS trials have progressed mainly in
kidney transplantation but currently have directed clinical trials toward anti-GBM
disease (Li et al., 2020). As previously mentioned, immunoadsorption removes
circulating anti-GBM antibodies with the use of sepharose-coupled antihuman IgG
but needs comprehensive validation before becoming an accepted technique.
Conclusion
Despite its rarity, Goodpasture syndrome has become increasingly better
understood since its initial description in 1958. Given the discovery of antibodies
and advancements in the field of molecular biology, affected individuals are able
to be diagnosed and treated through various methods. Effective patient
management is frequently achieved. The production of false-negative serology
results reduces the overall reliability of the diagnostic procedure, however. As the
disease can progress rapidly, an accurate diagnosis allowing for immediate
treatment is essential to prevent any detrimental consequences in the patient’s
health. Immunoadsorption and other alternate methods of treatment are being
researched and undergoing trials, with the potential of improving therapy efficacy.
Research into the type IV collagen family is also being conducted to improve
overall molecular understanding of the pathogenesis and progression of the disease
process. This may result in significant changes to the approach of disease
management and may improve patient recovery for future practice.
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